Breaking News, Collaborations & Alliances

WuXi Biologics, NBE-Therapeutics Enter ADC Devt. and Mfg. Tie-up

Partnership will enable the supply of NBE's product for clinical trials under IND applications worldwide

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi Biologics and NBE-Therapeutics (NBE) have entered a development and manufacturing partnership for NBE’s first ADC lead product NBE-002 (anti-ROR1). NBE-002 is a best-in-class immune-stimulatory ADC (iADC) treatment against the ROR1 cancer target and is planned to enter into clinical trials in mid 2020 in triple negative breast cancer and other indications.   NBE-Therapeutics develops next-generation iADC products with the aim to improve the outcome for cancer patients, as it continues...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters